Partial virological response to nucleos(t)ide analogues in naïve patients with chronic hepatitis B: From guidelines to field practice

Journal of Hepatology

Volumn 50, Issue 4, 2009, Pages 644-647

  Lampertico, Pietro ^a  

^a FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR; EMTRICITABINE; ENTECAVIR; LAMIVUDINE; NUCLEOSIDE ANALOG; TELBIVUDINE; TENOFOVIR; VIRUS DNA;

ADD ON THERAPY; ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; CLINICAL TRIAL; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; EDITORIAL; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; MEDICAL PRACTICE; MONOTHERAPY; PRACTICE GUIDELINE; PRIORITY JOURNAL; TREATMENT DURATION; VIREMIA; VIRUS LOAD;

ADENINE; ANTIVIRAL AGENTS; GUANINE; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; NUCLEOSIDES; NUCLEOTIDES; PHOSPHONIC ACIDS;

EID: 61749087369     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2009.01.007     Document Type: Editorial

References (17)

1. European Association for the Study of the Liver. EASL clinical practice guidelines: management of chronic hepatitis B. J Hepatol 2009;50:227-242.
2. Reijnders J.G.P., Pas S.D., Schutten M., de Man R.A., and Janssen H.L.A. Entecavir shows limited efficacy in HBeAg-positive hepatitis B patients with a partial virologic response to adefovir therapy. J Hepatol 50 (2009) 674-683
3. Lai C.-L., Gane E., Liaw Y.F., Hsu C.W., Thongsawat S., Wang Y., et al. Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med 357 (2007) 2576-2588
4. Liaw YF, Gane E, Leung N, Zeuzem S, Wang Y, Lai CL, et al. 2-Year GLOBE trial results: telbivudine is superior to lamivudine in patients with chronic hepatitis B. Gastroenterology 2009;136:486-495.
5. Safadi R., Xie Q., Chen Y., Yin Y.-K., Weis L., Hwang S.G., et al. A randomized trial of switching to telbivudine versus continued lamivudine in adults with chronic hepatitis B: results of the primary analysis at Week 24. J Hepatol 46 Suppl. 1 (2007) S196
6. Marcellin P., Heathcote E.J., Buti M., Gane E., de Man R.A., Krastev Z., et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med 359 (2008) 2442-2455
7. Hadziyannis S.J., Tassopoulos N.C., Heathcote E.J., Chang T.T., Kitis G., Rizzetto M., et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology 131 (2006) 1743-1751
8. Heathcote E.J., Gane E.J., de Man R.A., Chan S., Sievert W., Mauss S., et al. Two year tenofovir disoproxil fumarate (TDF) treatment and adefovir dipivoxil (ADV) switch data in HBeAg-positive patients with chronic hepatitis B (study 103), preliminary analysis. Hepatology 48 Suppl. (2008) 370A
9. Marcellin P., Buti M., Krastev Z., Gurel S., Balabanska R.I., Dusheiko G., et al. Two year tenofovir disoproxil fumarate (TDF) treatment and adefovir dipivoxil (ADV) switch data in HBeAg-negative patients with chronic hepatitis B (study 102), preliminary analysis. Hepatology 48 Suppl. (2008) 376A
10. Nguyen M.H., Trinh H.N., Garcia R.T., Nguyen L.H., Nguyen H.A., Nguyen K.K., et al. Treatment outcomes in patients with chronic hepatitis B (CHB) and partial response to adefovir (ADV) who were switched to entecavir (ETV). Hepatology 48 Suppl (2008) 711A
11. Chan H.L.Y., Heathcote E.J., Marcellin P., Lai C.L., Cho M., Moon Y.M., et al. Treatment of hepatitis B e antigen - positive chronic hepatitis with telbivudine or adefovir. Ann Intern Med 147 (2007) 745-754
12. Lai C.L., Shouval D., Lok A.S., Chang T.-T., Cheinquer H., Goodman Z., et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med 354 (2006) 1011-1120
13. Chang T.T., Gish R.G., de Man R., Gadano A., Sollano J., Chao Y.C., et al., for the behold AI463022 study group. A Comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 354 (2006) 1001-1010
14. Suzuki F., Akuta N., Suzuki Y., Yatsuji H., Sezaki H., Arase Y., et al. Selection of a virus strain resistant to entecavir in a nucleoside-nai{dotless}̈ve patient with hepatitis B of genotype H. J Clin Virol 39 (2007) 149-152
15. Guo JJ, Li QL, Shic XF, Zhang DZ, Zenga AZ, Feng T, et al. Dynamics of hepatitis B virus resistance to entecavir in a nucleoside/nucleotide-nai{dotless}̈ve patient. Antiviral Res 2008, doi:10.1016/j.antiviral.2008.09.004.
16. Pan C., and Hu K.Q. Excellent treatment response to tenofovir (TDF) monotherapy in chronic hepatitis B (CHB) patients with prior suboptimal response to entecavir (ETV) monotherapy. Hepatology 48 Suppl. (2008) 725A
17. Zoulim F., and Perrillo R. Hepatitis B: reflections on the current approach to antiviral therapy. J Hepatol 48 (2008) S2-S19